Bausch Health Companies Inc.: Hepatitis trials

The registry lists 11 Hepatitis studies with Bausch Health Companies Inc. as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 2 6Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)RecruitingNCT07428538Phase 3
• A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic HepatitisCompletedNCT03432260Phase 2Results posted
• Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)CompletedNCT00446134Phase 2Results posted
• A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentCompletedNCT04563026Phase 2
• Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis CTerminatedNCT00305383Phase 2
• Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-NaiveCompletedNCT00230958Phase 3
• Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis BCompletedNCT00230503Phase 2
• Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201TerminatedNCT00230490Phase 2
• Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined TherapyCompletedNCT00162734Phase 3
• Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment NaiveCompletedNCT00093093Phase 3
• Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined TherapyCompletedNCT00086541Phase 3